NZ706302A - Sublingual wafer solid dosage form containing amylopectin - Google Patents

Sublingual wafer solid dosage form containing amylopectin

Info

Publication number
NZ706302A
NZ706302A NZ706302A NZ70630213A NZ706302A NZ 706302 A NZ706302 A NZ 706302A NZ 706302 A NZ706302 A NZ 706302A NZ 70630213 A NZ70630213 A NZ 70630213A NZ 706302 A NZ706302 A NZ 706302A
Authority
NZ
New Zealand
Prior art keywords
dosage form
solid dosage
form containing
containing amylopectin
amylopectin
Prior art date
Application number
NZ706302A
Other languages
English (en)
Inventor
Yip Hang Eddy Lee
Chin Beng Stephen Lim
Vivian Bruce Sunderland
Original Assignee
Ix Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012238330A external-priority patent/AU2012238330B1/en
Application filed by Ix Biopharma Ltd filed Critical Ix Biopharma Ltd
Publication of NZ706302A publication Critical patent/NZ706302A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • A61K38/063Glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ706302A 2012-10-11 2013-10-11 Sublingual wafer solid dosage form containing amylopectin NZ706302A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012238330A AU2012238330B1 (en) 2010-10-26 2012-10-11 Fast Dissolving Solid Dosage Form
AU2013200684A AU2013200684B1 (en) 2010-10-26 2013-02-08 Fast Dissolving Solid Dosage Form
AU2013200682A AU2013200682C1 (en) 2010-10-26 2013-02-08 Fast Dissolving Solid Dosage Form
PCT/IB2013/002594 WO2014057351A1 (fr) 2012-10-11 2013-10-11 Forme de dosage solide

Publications (1)

Publication Number Publication Date
NZ706302A true NZ706302A (en) 2017-07-28

Family

ID=50478109

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ706302A NZ706302A (en) 2012-10-11 2013-10-11 Sublingual wafer solid dosage form containing amylopectin

Country Status (11)

Country Link
EP (1) EP2906201A4 (fr)
JP (1) JP2015533155A (fr)
KR (1) KR20150063567A (fr)
CN (2) CN107669649A (fr)
CA (1) CA2886573C (fr)
HK (1) HK1208353A1 (fr)
IL (2) IL238104B (fr)
MY (1) MY191875A (fr)
NZ (1) NZ706302A (fr)
SG (1) SG11201502425WA (fr)
WO (1) WO2014057351A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6217052B2 (ja) * 2016-04-21 2017-10-25 邦赫 小牧 口腔清浄用発泡性錠剤
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
WO2017192921A1 (fr) 2016-05-05 2017-11-09 Monosol Rx, Llc Compositions d'épinéphrine à administration améliorée
JP2017193547A (ja) * 2017-05-08 2017-10-26 邦赫 小牧 口腔清浄用発泡性錠剤
KR20200060748A (ko) * 2017-09-27 2020-06-01 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 및 프로드러그 조성물
EP3687509A1 (fr) * 2017-09-27 2020-08-05 Aquestive Therapeutics, Inc. Compositions pharmaceutiques à perméation améliorée
IT201800003507A1 (it) * 2018-03-13 2019-09-13 Fulton Medicinali S P A Compressa sublinguale comprendente sildenafil citrato
SMT202600055T1 (it) * 2019-01-07 2026-03-09 Antecip Bioventures Ii Llc Combinazione di destrometorfano e bupropione per trattare la depressione in pazienti asiatici
CN109846841B (zh) * 2019-01-18 2021-06-01 西安力邦医药科技有限责任公司 一种速效氯巴占口服冻干制剂及其制备方法
US12589083B2 (en) * 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11382873B1 (en) * 2021-01-08 2022-07-12 Vitalis Analgesics LLC Oral administration of ketamine
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
WO2025120580A1 (fr) * 2023-12-08 2025-06-12 Ix Biopharma Ltd Compositions et méthodes pour induire une réponse immunitaire mucosale

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
AU2001273545A1 (en) * 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
EP2343045A3 (fr) * 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Système d'administration de médicament par voie transmucosique
CA2612917A1 (fr) * 2005-06-23 2007-01-04 Schering Corporation Formulations orales a absorption rapide d'inhibiteurs de la pde5
KR100905027B1 (ko) * 2007-10-03 2009-06-30 (주)씨엘팜 식용 필름
WO2009045022A2 (fr) * 2007-10-03 2009-04-09 C.L. Pharm Film comestible
DE102008014533A1 (de) * 2008-03-15 2009-09-17 Lts Lohmann Therapie-Systeme Ag Gingival-Wafer
US8623401B2 (en) * 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
DK2493457T3 (en) * 2009-10-30 2017-10-02 Ix Biopharma Ltd QUICK-SOLVING SOLID DOSAGE FORM
CN103025321A (zh) * 2010-03-23 2013-04-03 生物联合制药公司 快速溶解的药物释放系统
FR2967066B1 (fr) * 2010-11-04 2013-06-14 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes
JP5841433B2 (ja) * 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
AU2014233363B2 (en) * 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases

Also Published As

Publication number Publication date
KR20150063567A (ko) 2015-06-09
IL273076A (en) 2020-04-30
MY191875A (en) 2022-07-18
IL238104B (en) 2020-03-31
EP2906201A1 (fr) 2015-08-19
EP2906201A4 (fr) 2016-10-19
SG11201502425WA (en) 2015-05-28
IL238104A0 (en) 2015-05-31
WO2014057351A1 (fr) 2014-04-17
CN107669649A (zh) 2018-02-09
CN104812378A (zh) 2015-07-29
CN104812378B (zh) 2017-12-01
CA2886573C (fr) 2019-04-02
JP2015533155A (ja) 2015-11-19
CA2886573A1 (fr) 2014-04-17
HK1208353A1 (en) 2016-03-04

Similar Documents

Publication Publication Date Title
NZ706302A (en) Sublingual wafer solid dosage form containing amylopectin
MY150626A (en) Fast dissolving solid dosage form
PH12013501821A1 (en) Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
TN2010000152A1 (en) Pharmaceutical compositions
MX361413B (es) Formas cristalinas de un macrólido y usos para las mismas.
MX2013007057A (es) Metodos para producir composiciones farmaceuticas estabilizadas de dosis solida que contienen morfinanos.
MX393195B (es) Capsula de estradiol soluble para insercion por via vaginal
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
MY194495A (en) Compositions and methods for transmucosal absorption
PE20140255A1 (es) Tableta dispersable en forma oral
IN2014MN02245A (fr)
PL2217219T3 (pl) Podjęzykowa musująca tabletka progesteronu w połączeniu z cyklodekstryną
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
PH12014501288A1 (en) Oral care compositions
IN2013CH05441A (fr)
MX2015011109A (es) Composiciones estables de activador de glucoquinasa.
TN2015000135A1 (en) Modified release formulations for oprozomib
PH12014502834A1 (en) Pharmaceutical form for extended release of active substances
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
PH12013501552A1 (en) Oral care compositions
AR062925A1 (es) Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
PH12014501304B1 (en) Oral care compositions
MY197454A (en) Non-enteric pharmaceutical composition comprising crofelemer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2019 BY WRAYS

Effective date: 20180713

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2020 BY WRAYS PTY LTD

Effective date: 20190927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2021 BY WRAYS PTY LTD

Effective date: 20200923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2022 BY WRAYS PTY LTD

Effective date: 20210928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2023 BY WRAYS PTY LTD

Effective date: 20220930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2024 BY WRAYS PTY LTD

Effective date: 20230913

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2025 BY WRAYS PTY LTD

Effective date: 20240913

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2026 BY WRAYS PTY LTD

Effective date: 20250930